"Medical Dermatology is our specialty with expertise in autoimmune skin diseases, psoriasis, atopic dermatitis, blistering skin diseases as well as wound care, cinical trials and more common skin condtions like warts, acne, moles, seborrhea, rosacea. For more details, please see fivensondermatology."

During the past decade, David Fivenson, MD, PLC conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 8 clinical trials were completed, i.e. on average, 72.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "David Fivenson, MD, PLC" #1 sponsor was "Eli Lilly and Company" with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "LEO Pharma" with 2 trials sponsored, "AKARI Therapeutics" with 1 trials sponsored and "Actavis Inc." with 1 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "David Fivenson, MD, PLC" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator and "Prosoft Clinical" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "David Fivenson, MD, PLC" are "Atopic Dermatitis" (5 trials), "Psoriasis" (5 trials), "Plaque Psoriasis" (3 trials), "Psoriasis Vulgaris" (2 trials) and "Bullous Pemphigoid" (1 trials). Many other conditions were trialed in "David Fivenson, MD, PLC" in a lesser frequency.

Most popular intervention types in "David Fivenson, MD, PLC" are "Drug" (17 trials), "Other" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "BMS-986165" (2 trials), "Guselkumab" (2 trials), "LEO 90100" (2 trials) and "Lebrikizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "David Fivenson, MD, PLC" are 21 trials for "All" genders.

Currently, there are NaN active trials in "David Fivenson, MD, PLC". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in David Fivenson, MD, PLC, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in David Fivenson, MD, PLC, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".